Stéphane Mancini

@stephanemancini.bsky.social

INSERM Research Director, passionate about Science, Immunology, Hematology, lymphocytes, leukemia, microenvironment. Keen on cytometry, imaging, bioinformatics

🚨🦠🔬 Last month to register to the EMBO workshop on Adaptive Immunity in Barrier Tissues. 📍 Where: Basel, Switzerland 📅 When: 26th–29th August 2025 📝 Registration deadline: 30th May 2025 Childcare support & travel grants from @embo.org and @efis-immunology.bsky.social #EMBOBarrierTissues

Adaptive immunity in barrier tissues

Immune responses lie at the heart of almost every aspect of human health, including host responses to infection, autoimmunity, cancer, metabolism and aging. While adaptive immune responses by B and T…

meetings.embo.org

Extremely happy to share our study on the regulation of HSCs in the context of myocardial infarction published in Nature Cell Biology! Driven by two amazing scientists in my lab - Jasmin and Maricarmen and co-led with the awesome cardiologist Timo! Huge thanks also to all our collaborators 👏🏻👏🏻

Max Planck Institute of Immunobiology and Epigenetics@mpi-ie.bsky.social · 2y ago

New research by the @ninacabezas.bsky.social lab & collaborators from @uniklinik-fr.bsky.social. A vitamin A metabolite may offer a targeted therapeutic strategy for heart attack patients by regulating HSCs to minimize excessive inflammation and preserve long-term heart function.

‘I hate to predict things’: Trump doesn’t rule out US recession amid trade tariffs Ah ah! 😂 That’s why he has been so successful in sinking daddy’s fortune. Well now the problem is that he is sinking the US and the whole world ☹️

So happy to share the latest preprint of the lab, with Marjorie Delahaye as the main actor of this great story. This work demonstrates that the bone marrow microenvironment can imprint (pre-)leukemic cell fate and influence the acquisition of secondary mutations

Signals from the bone marrow B cell niches shape pre-leukemic fate in murine B cell acute lymphoblastic leukemia

The bone marrow (BM) microenvironment plays a key role in supporting B cell development. In acute lymphoblastic leukemia (B-ALL), the acquisition of oncogenic driver mutations blocks B cell differenti...

biorxiv.org

🎉 We’re excited to share our latest research on FLT3-targeted antibody-drug conjugates (ADCs) as a promising strategy to eliminate leukemic stem cells in AML! 🚀🔬Many thanks to all involved in this great BMBF-funded project #leukemia #PDXmodels 📖Read more here: www.nature.com/articles/s41...

Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates - Leukemia

Leukemia - Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates

nature.com